Download - Dr. Hebbar of CalciMedica Talks Auxora Clinical Trial Targeting COVID-19, CRAC, and More

Discover

Podcast Features
Your all-in-one podcasting solution.

Blog to Podcast
Turn your blog into an engaging podcast.
Livestream
High-performing audio live, without limits.

Podcast Studio
Easy-to-use audio recorder app.
Podbean AI
AI-Enhanced Audio Quality and Content Generation.

Podcast App
The best podcast player & podcast app.

Ads Marketplace
Join Ads Marketplace to earn money
through sponsorship on your podcast.

PodAds
Manage your ads with dynamic ad insertion capability.
Apple Podcasts Subscriptions Integration
Effortlessly publish and manage exclusive episodes for your
Apple Podcasts subscribers directly from Podbean.
Live Streaming
Receive livestream rewards from your audience and earn
recurring income from your Fan Club membership.

All Arts Business Comedy Education
Fiction Government Health & Fitness History Kids & Family
Leisure Music News Religion & Spirituality Science
Society & Culture Sports Technology True Crime TV & Film
Live

How to Start a Podcast
How to Start a Live Podcast
How to Monetize a podcast
How to Promote Your Podcast
How to Use Group Recording

Log in
Start your podcast for free

Podcasting
Monetization
Advertisers
Enterprise
Pricing
Discover

trialsitenews's podcast

News

Dr. Hebbar of CalciMedica Talks Auxora Clinical Trial Targeting COVID-19, CRAC, and More

2020-09-23

Download Right click and do "save link as"

Today we have Dr. Hebbar from CalciMedica joining us today. Dr. Hebbar has 10+ years of clinical development and product development experience in both the pharmaceutical and diagnostics industries. Now, Privately held CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases. Founded in 2007 the San Diego-based company focuses on the discovery and development of CRAC channel inhibitor drugs. With the onset of the pandemic the company registered studies targeting severe COVID-19 pneumonia, a dangerous condition.